Compare VAL & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | TWST |
|---|---|---|
| Founded | 1975 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.4B |
| IPO Year | 2021 | 2018 |
| Metric | VAL | TWST |
|---|---|---|
| Price | $78.81 | $118.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $70.86 | ★ $128.92 |
| AVG Volume (30 Days) | 667.3K | ★ 2.3M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $2,369,000,000.00 | $459,433,000.00 |
| Revenue This Year | N/A | $21.01 |
| Revenue Next Year | $11.75 | $18.75 |
| P/E Ratio | $67.44 | ★ N/A |
| Revenue Growth | 0.27 | ★ 22.00 |
| 52 Week Low | $48.09 | $25.67 |
| 52 Week High | $114.12 | $219.71 |
| Indicator | VAL | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 41.08 |
| Support Level | $74.47 | $79.90 |
| Resistance Level | $81.10 | $153.47 |
| Average True Range (ATR) | 4.19 | 14.82 |
| MACD | -1.32 | -2.38 |
| Stochastic Oscillator | 7.06 | 28.56 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.